We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 8186O
Silence Therapeutics PLC
11 February 2021
TR-1: Standard form for notification of major holdings
Hot Features
Premium
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in
Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer Silence Therapeutics plc
of existing shares to which voting rights are
attached ii :
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights x
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify) iii :
----
3. Details of person subject to the notification obligation iv
Name LOIM Lombard Odier Asset Management (Europe) Limited
---------------------------------------------------------------
City and country of registered office LondonUnited Kingdom
(if applicable)
---------------------------------------------------------------
4. Full name of shareholder(s) (if different from 3.) v
Name
---------------------------------------------------------------
City and country of registered office
(if applicable)
---------------------------------------------------------------
5. Date on which the threshold was crossed 08/02/2021
or reached vi :
6. Date on which issuer notified (DD/MM/YYYY): 09/02/2021
---------------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total of both in Total number
attached through financial % (8.A + 8.B) of voting rights
to shares (total of instruments (total of issuer vii
8. A) of 8.B 1 + 8.B 2)
-------------------------- ----------------------- ----------------- -------------------
Resulting situation
on the date on which
threshold was crossed
or reached 8.36% 1.50% 9.86% 83,315,259
-------------------------- ----------------------- ----------------- -------------------
Position of previous
notification (if
applicable) 10.96% 1.94% 12.90%
-------------------------- ----------------------- ----------------- -------------------
ISIN CODE (if possible)
GB00B9GTXM62 Ordinary
SUBTOTAL 8. A
8. Notified details of the resulting situation on the date on which the threshold was
crossed or reached viii
A: Voting rights attached to shares
Class/type of Number of voting rights ix % of voting rights
shares
ISIN CODE (if possible)
Direct (Art 9 of Indirect (Art 10 Direct (Art 9 of Indirect (Art
Directive of Directive Directive 2004/109/EC) 10 of Directive
2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.2.1) (DTR5.2.1)
GB00B9GTXM62 Ordinary 6,966,150 8.36%
---------------------- ----------------------- ----------------------- ----------------
SUBTOTAL 8. A 6,966,150 8.36%
----------------------------------------------- -----------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1
(a))
Number of voting % of voting rights
Type of financial Expiration Exercise/ rights
instrument date x Conversion Period that may be acquired
xi if
the instrument is
exercised/converted.
ADR US82686Q1013 1,250,344 1.50%
------------------
SUBTOTAL 8. B 1 1,250,344 1.50%
-------------------- --------------------- ------------------
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of
Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial Expiration Exercise/ Physical Number of voting % of voting rights
instrument date x Conversion or cash rights
Period xi settlement
xii
CASH
----------- ----------- ----------- ---------------- ------------------
SUBTOTAL
8.B.2
----------- ---------------- ------------------
9. Information in relation to the person subject to the notification obligation (please
mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person x
or legal entity and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer xiii
----
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling
natural person or legal entity xiv (please add additional rows as necessary)
----
Name xv % of voting rights % of voting rights Total of both if it
if it equals or is through financial equals or is higher
higher than the notifiable instruments if it than the notifiable
threshold equals or is higher threshold
than the notifiable
threshold
--------------------------- -------------------- -----------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be
held
11. Additional information xvi
Place of completion London
Date of completion 09/02/2021
----------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLUARARASUUAAR
(END) Dow Jones Newswires
February 11, 2021 06:06 ET (11:06 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
